Given's PillCam gets Italian reimbursement boost:
This article was originally published in Clinica
Given Imaging has secured wider access for its PillCam endoscopy "video pill" in Europe, with the approval of its reimbursement in Italy's Piedmont region. The decision supports the use of the technology - until recently known as M2A - as an outpatient procedure in the treatment of a number of small bowel disorders, including Crohn's disease, coeliac disease, lymphoma, polyposis and occult bleeding. The Yoqneam, Israel-based specialist in capsule endoscopy claims that the approval by the regional government of Piedmont, with 4.3 million people, extends PillCam's reimbursement coverage to an EU-wide population of around 44 million. Given Imaging rebranded the M2A video capsule as PillCam on September 9 (see Clinica No 1124, p 17).
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.